BioClinica expands in Europe with a focus on imaging

CRO BioClinica has opened new outposts in the U.K. and Germany, expanding its European footprint and scaling up its capabilities in medical imaging.

The new facilities, in London and Munich, span a combined 1,400 square meters and will support clinical trials around the continent. BioClinica, which has largely made its name through its eClinical offerings, will pay particular attention to medical imaging, establishing an image analysis center for its network of European radiologists.

"Our expansion will provide the resources needed for regional scientific and medical experts to assemble and deliver high-quality central review of imaging data for multisite trials in Europe," BioClinica imaging president David Herron said in a statement.

The new operations will also expand the CRO's banner eClinical arm, the company said, creating an interactive environment in which European clients can try out BioClinica's trial technology.

Meanwhile, BioClinica has been investing in its capabilities in risk-based monitoring and trial safety. The acquisitive company has spent the past few years buying up new technologies, including offerings in electronic data collection, patient randomization and supply management.

BioClinica, which is privately held, said its eClinical sales jumped 51% last year, reflecting a spike in Big Pharma's adoption of new trial technologies. The company reported 25 new partnerships last year and now boasts a client roster of more than 150, and its buyouts have grown its payroll to more than 1,300 people around the world.

- read the statement

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.